Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Metsera, a young biotech company, is at the heart of a fierce takeover war between Novo Nordisk and Pfizer, both vying for its experimental weight-loss treatments. Metsera's lead drug, MET-097i, offers a monthly injection targeting a protein pathway linked to weight loss and insulin release, potentially outperforming Novo's Wegovy and Eli Lilly's Zepbound. With promising drugs and major investors, Metsera's value has doubled since its IPO, and its shares have surged. The bidding war has investors buzzing, with shares of Viking Therapeutics and Structure Therapeutics also surging, as the sector chases the next big thing in weight loss and metabolic health.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.